# Peter A. Merkel

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/peter-a-merkel/

## Facts

| Field | Value |
| --- | --- |
| Citations | 62,470 |
| Field | Vasculitis and related conditions |
| h-index | 114 |
| i10-index | 364 |
| Last Known Institution | University of Pennsylvania |
| OpenAlex ID | https://openalex.org/A5106744504 |
| ORCID iD | https://orcid.org/0000-0001-9284-7345 |
| Works | 663 |

## Researcher papers

Showing 12 of 15.

- [2012 Revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides](https://scholariq.org/papers/2012-revised-international-chapel-hill-consensus-conference-nomenclature-of-2/)
- [Rituximab versus Cyclophosphamide for ANCA-Associated Vasculitis](https://scholariq.org/papers/rituximab-versus-cyclophosphamide-for-anca-associated-vasculitis/)
- [Estimates of the prevalence of arthritis and other rheumatic conditions in the United States: Part I](https://scholariq.org/papers/estimates-of-the-prevalence-of-arthritis-and-other-rheumatic-conditions-in-the-2/)
- [2012 Revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides](https://scholariq.org/papers/2012-revised-international-chapel-hill-consensus-conference-nomenclature-of/)
- [EULAR/ERA-EDTA recommendations for the management of ANCA-associated vasculitis](https://scholariq.org/papers/eular-era-edta-recommendations-for-the-management-of-anca-associated-vasculitis/)
- [Mepolizumab or Placebo for Eosinophilic Granulomatosis with Polyangiitis](https://scholariq.org/papers/mepolizumab-or-placebo-for-eosinophilic-granulomatosis-with-polyangiitis/)
- [ANCA-associated vasculitis](https://scholariq.org/papers/anca-associated-vasculitis/)
- [Efficacy of Remission-Induction Regimens for ANCA-Associated Vasculitis](https://scholariq.org/papers/efficacy-of-remission-induction-regimens-for-anca-associated-vasculitis/)
- [EULAR recommendations for the management of ANCA-associated vasculitis: 2022 update](https://scholariq.org/papers/eular-recommendations-for-the-management-of-anca-associated-vasculitis-2022/)
- [A multicenter, randomized, double‐blind, placebo‐controlled trial of adjuvant methotrexate treatment for giant cell arteritis](https://scholariq.org/papers/a-multicenter-randomized-double-blind-placebo-controlled-trial-of-adjuvant/)
- [Eosinophilic granulomatosis with polyangiitis (Churg–Strauss) (EGPA) Consensus Task Force recommendations for evaluation and management](https://scholariq.org/papers/eosinophilic-granulomatosis-with-polyangiitis-churg-strauss-egpa-consensus-task/)
- [A disease-specific activity index for Wegener's granulomatosis: Modification of the Birmingham Vasculitis Activity Score](https://scholariq.org/papers/a-disease-specific-activity-index-for-wegener-s-granulomatosis-modification-of/)

## Researcher topics

- [Vasculitis and related conditions](https://scholariq.org/topics/vasculitis-and-related-conditions-2/)
- [Otitis Media and Relapsing Polychondritis](https://scholariq.org/topics/otitis-media-and-relapsing-polychondritis/)
- [Systemic Sclerosis and Related Diseases](https://scholariq.org/topics/systemic-sclerosis-and-related-diseases/)
- [Rheumatoid Arthritis Research and Therapies](https://scholariq.org/topics/rheumatoid-arthritis-research-and-therapies/)
- [Coagulation, Bradykinin, Polyphosphates, and Angioedema](https://scholariq.org/topics/coagulation-bradykinin-polyphosphates-and-angioedema/)

## Researcher university

- [University of Pennsylvania](https://scholariq.org/institutions/university-of-pennsylvania/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.